Introduction
============

The cullin-RING ubiquitin ligases (CRLs) are the largest E3 ligase family in eukaryotes, and ubiquitinate a wide array of substrates involved in cell cycle, signaling, DNA damage response, gene expression, chromatin remodeling, and embryonic development. Cullins serve as elongated scaffolds that assemble functional E3 complexes by utilizing distinct adaptors to recruit substrate receptors and the ubiquitin-charged E2 conjugating enzyme (Figure [1](#F1){ref-type="fig"}). Within the E2--E3 complex, the RING domain-containing Rbx1/ROC1/Hrt1 or Rbx2/SAG adaptor bridges E2 binding to the cullin carboxyl terminus, which is necessary for transfer of ubiquitin to all cullin substrates. The cullin amino terminus binds cullin-specific adaptors, which in turn recruit distinct classes of substrate receptors that target substrates to the E2--CRL complex for ubiquitination and subsequent degradation by the 26S proteasome. CRL activity is regulated by the Nedd8 post-translational modification: the ubiquitin-like Nedd8 protein is conjugated to cullins in a manner highly analogous to ubiquitination. In a cascade of events designated the neddylation cycle, neddylation promotes CRL activity, while deneddylation by the COP9 signalosome inhibits cullins (reviewed in Petroski and Deshaies, [@B62]; Sarikas et al., [@B66]).

![**Schematic diagram of the multimeric CRL ubiquitin ligase complex**. The elongated cullin scaffold binds cullin-specific adaptors (CA) at the N-terminus to recruit substrates (S). All cullins except CUL3 require separate substrate receptors (SR) to bridge the adaptor--substrate interaction. RING protein adaptors (R) bind the ubiquitin (Ub)-charged E2 conjugating enzyme at the cullin C-terminus. Nedd8 post-translational modification (N) promotes cullin activity.](fonc-02-00021-g001){#F1}

Among the eight cullins (CUL1-7 and PARC) in higher organisms, the CUL4 subfamily of CRLs is uniquely comprised of two members, CUL4A and CUL4B, that share extensive sequence homology and functional redundancy. While most cullins recruit substrate receptors using BTB domain-containing adaptors, the CUL4 family employs the structurally distinct triple WD40 β-propeller domain-containing DDB1 adaptor to recruit members of the DDB1--CUL4 associated factors (DCAF) family of substrate receptors (Angers et al., [@B4]; He et al., [@B21]; Higa et al., [@B23]; Jin et al., [@B34]; reviewed in Lee and Zhou, [@B43]). Genetic approaches have been utilized to dissect the physiological relevance and unique functions of the CUL4 family members, as well as the individual components of the CRL4 ubiquitin ligase complex (Yoon et al., [@B88]; Kopanja et al., [@B41], [@B40]; Liu et al., [@B49]; Yin et al., [@B87]). This focused review will summarize recent findings that have shed light on the role of CUL4 activity in human disease.

CUL4A and Cancer
================

*CUL4A* was initially identified as an amplified or overexpressed gene in primary human breast cancers (Chen et al., [@B10]). Genome-wide analysis of human cancers revealed *CUL4A* amplification in 5% of familial and sporadic breast cancers, and as high as 20% in the basal-like breast cancer subtype that is associated with aggressive growth and poor prognosis (Melchor et al., [@B51]). *CUL4A* amplification has also been found in squamous cell carcinomas (Shinomiya et al., [@B69]), adrenocortical carcinomas (Dohna et al., [@B15]), childhood medulloblastoma (Michiels et al., [@B52]), hepatocellular carcinomas (Yasui et al., [@B86]), and primary malignant pleural mesotheliomas (Hung et al., [@B29]). Recently, genome-wide high-density SNP arrays further revealed high *CUL4A* gene copy number in a subset of lung and ovarian carcinomas, as well as other solid tumor types (Beroukhim et al., [@B7]). Moreover, high CUL4A expression correlates with significantly shorter overall and disease-free survival (Schindl et al., [@B67]), indicating that dysregulation of CUL4A may play a role in promoting oncogenesis. Mouse models support this hypothesis, as skin-specific *Cul4a* knockout mice showed marked resistance to UV-induced carcinogenesis compared to wild-type and heterozygous mice (Liu et al., [@B49]). Transgenic mice with inducible expression of exogenous CUL4A developed pulmonary hyperplasia, which is consistent with a role for dysregulated CUL4A in driving uncontrolled proliferation (Li et al., [@B46]). The role of CUL4B in carcinogenesis remains to be determined.

The damaged DNA binding proteins DDB1 and DDB2 were first characterized as DNA damage sensors that initiate the nucleotide excision repair (NER) pathway following UV irradiation (reviewed in Tang and Chu, [@B77]). Earlier studies identified the DDB1--DDB2 heterodimer as both a target and component of the CRL4 ubiquitin ligase complex (Shiyanov et al., [@B70]; Chen et al., [@B11]; Nag et al., [@B54]; Groisman et al., [@B19]). *DDB2* mutations that impair the recognition of UV-induced DNA lesions are causal for the photosensitivity and early onset of skin cancer found in xeroderma pigmentosum group E (XPE) patients (Nichols et al., [@B56]), and were recapitulated in the *Ddb2* knockout mouse model (Itoh et al., [@B32]; Yoon et al., [@B88]; Alekseev et al., [@B3]). Conversely, enforced expression of *DDB2* in transgenic mice delayed the onset of UV-induced squamous cell carcinomas (Alekseev et al., [@B3]), further highlighting the significance of DDB2 activity in DNA repair and cancer prevention. The physiological relevance of CUL4A-mediated degradation of DDB2 was determined in the *Cul4a* knockout mouse, as skin-specific deletion of CUL4A significantly enhanced resistance to UV-induced skin carcinogenesis (Liu et al., [@B49]). Protein levels of DDB2 and XPC, another NER damage sensor and CRL4^DDB2^ substrate (Sugasawa et al., [@B73]), were found to accumulate, thus augmenting NER activity and decreasing tumorigenic potential.

In addition to DNA repair, CRL4 also plays a significant role in cell cycle regulation by targeting the Cdt1 DNA replication licensing factor, the p21 cyclin-dependent kinase inhibitor, and the PR-Set7/Set8 histone H4K20 methyltransferase for ubiquitin-proteolytic degradation in a Cdt2 (DCAF)- and PCNA-dependent manner (Higa et al., [@B22]; Zhong et al., [@B91]; Hu et al., [@B26]; Jin et al., [@B34]; Nishitani et al., [@B58], [@B57]; Abbas et al., [@B2], [@B1]; Kim et al., [@B39]; Centore et al., [@B9]; Oda et al., [@B59]; Tardat et al., [@B78]; Jorgensen et al., [@B35]). Knockdown of Cdt2 resulted in G2 arrest and DNA re-replication of the genome (Jin et al., [@B34]), indicating a critical role for CRL4^Cdt2^ in limiting the replication of DNA during S phase. In response to UV or ionizing radiation, Cdt1, p21, and PR-Set7/Set8 were rapidly degraded in a CRL4-dependent manner (Higa et al., [@B22]; Hu et al., [@B26]; Abbas et al., [@B2], [@B1]; Centore et al., [@B9]; Jorgensen et al., [@B35]). S phase arrest is also triggered by CRL4-mediated degradation of Chk1 in a phosphorylation-dependent manner under normal conditions and in the presence of genotoxic stress (Zhang et al., [@B90]; Leung-Pineda et al., [@B44]). While these proteins are targeted by both CUL4 family members, p21 protein levels were found to accumulate in primary *Cul4a*^−*/*−^ mouse embryonic fibroblasts (MEFs) following UV irradiation, resulting in prolonged G1/S arrest (Liu et al., [@B49]). Higher p21 levels enforced the G1/S cell cycle checkpoint post-UV, thus allowing additional time for NER activities to conclude prior to the initiation of DNA replication. The absence of G2 arrest or DNA re-replication in the *Cul4a* knockout mouse model indicates that CUL4B at least partially compensates for the loss of CUL4A activity. Simultaneous inactivation of both CUL4A and CUL4B in primary MEFs led to growth arrest (Liu et al., [@B49]), which recapitulates the rapid G1 arrest observed in DDB1 knockout MEF cells (Cang et al., [@B8]).

Conflicting reports indicate that additional cell cycle regulators may be targeted by CRL4-based ubiquitin ligases for proteasome-mediated degradation. CUL4A overexpression reduced the steady-state levels of the CDK inhibitor p27^Kip1^ in 293T cells, while CUL4A shRNA or dominant-negative CUL4A resulted in the accumulation of p27^Kip1^ in mouse mammary epithelial cells or the human MCF-7 breast cancer cell, respectively (Miranda-Carboni et al., [@B53]). However, the turnover rate of p27^Kip1^ was not directly measured under these conditions. Using primary MEF cells, Cang et al. ([@B8]) showed that deletion of DDB1 resulted in G1/S cell cycle arrest and p27^Kip1^ accumulation. However, the half-life of p27 was not prolonged in the absence of DDB1, arguing against p27^Kip1^ as a direct substrate of the CRL4 ubiquitin ligase. Future studies should determine whether a CRL4-based E3 ligase directly or indirectly regulates p27^Kip1^ protein stability. Interestingly, silencing of CUL4B in primary MEF cells had little effect on cell proliferation (Liu et al., [@B49]), but CUL4B knockdown in HeLa cells resulted in S phase cell cycle arrest (Zou et al., [@B92]) as well as cyclin E accumulation (Higa et al., [@B24]; Zou et al., [@B93]). Given the stimulatory role of cyclin E in S phase progression and cell proliferation, it remains to be determined how increased cyclin E levels would result in growth inhibition, and whether additional CUL4B substrates are also involved in triggering S phase arrest.

The amplification or overexpression of *CUL4A* observed in various cancers likely corresponds with diminished post-translational stability of its substrates, many of which are tumor suppressors (Table [1](#T1){ref-type="table"}). CRL4^Fbw5^ may promote oncogenesis by targeting the mTOR inhibitor tuberous sclerosis protein 2 (Tsc2) for ubiquitination (Hu et al., [@B27]). Mutations in the Tsc1 and Tsc2 tumor suppressors are causal for the synonymous autosomal dominant disease that is marked by the formation of benign growths on the skin, nervous system, kidneys, and heart. REDD1, another inhibitor of mTOR signaling, is targeted for degradation by the CRL4^βTrCP^ ubiquitin ligase (Katiyar et al., [@B37]). Additional tumor suppressors that are subject to CUL4A-mediated ubiquitination include p150/Sal2, which is degraded as cells transition from quiescence to an actively dividing state (Sung et al., [@B74]), and RASSF1A (Jiang et al., [@B33]), a negative Ras effector that was previously identified as a target of the CRL1/SCF^Skp2^ (Skp1, CUL1, F-box-containing substrate receptor, and Rbx1) ubiquitin ligase (Song et al., [@B71]). Contrary to the trend of CUL4A-mediated degradation of tumor suppressors, the CRL4 substrate receptor TRCP4AP/TRUSS targets both N-Myc and C-Myc transcription factors for degradation (Choi et al., [@B12]). Stabilization of Myc protein in many cancer cell lines corresponds with TRCP4AP/TRUSS downregulation, indicating the potential significance of CUL4-mediated post-translational regulation in restricting Myc protein levels. COP1, acting as a CRL4 substrate receptor, functions as a tumor suppressor by targeting the c-Jun proto-oncogene for ubiquitination (Wertz et al., [@B84]). However, tissue-specific differences have been reported in CRL4-independent COP1 ubiquitin ligase activity. The p53 tumor suppressor is targeted for degradation by COP1 (Dornan et al., [@B16]), which may provide mechanistic insight into COP1 overexpression observed in ovarian and breast cancer. Conversely, the oncogenic ETS transcription factors are also degraded in a COP1-dependent manner, and loss of COP1 activity results in ETV1 accumulation that promotes prostate epithelial cell proliferation (Vitari et al., [@B81]). Finally, ectopic expression of *CUL4A* in PC12 rat pheochromocytoma cells suppresses apoptosis and promotes cell survival (Tan et al., [@B75]), further indicating that CUL4A activity supports cell growth.

###### 

**Involvement of CUL4A substrates in pathogenesis**.

  DCAF            Substrate      Substrate functions                                    Associated pathogenesis                                   Reference
  --------------- -------------- ------------------------------------------------------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  DDB2            DDB2           Nucleotide excision repair; DCAF substrate receptor.   Xeroderma pigmentosum; skin cancer                        Nichols et al. ([@B56]), Chen et al. ([@B11]), Groisman et al. ([@B19]), Nag et al. ([@B54]), Sugasawa et al. ([@B73])
  DDB2            XPC            Nucleotide excision repair                             Xeroderma pigmentosum, skin cancer                        Sugasawa et al. ([@B73])
  Cdt2            p21/CIP/WAF1   CDK inhibitor                                          Normal cell cycle and DNA damage response                 Abbas et al. ([@B2]), Kim et al. ([@B39]), Nishitani et al. ([@B57])
  Cdt2            Cdt1           DNA replication licensing factor                       DNA re-replication                                        Higa et al. ([@B23]), Jin et al. ([@B34])
  Cdt2            PR-Set7/Set8   Histone methyltransferase                              Unknown                                                   Abbas et al. ([@B1]), Centore et al. ([@B9]), Jorgensen et al. ([@B35]), Oda et al. ([@B59]), Tardat et al. ([@B78])
  Fbw5            Tsc2           Inhibitor of mTOR signaling                            Tuberous sclerosis                                        Hu et al. ([@B27])
  β-TrCP          REDD1          Inhibitor of mTOR signaling                            unknown                                                   Katiyar et al. ([@B37])
  RBBP7           p150/Sal2      Inhibitor of cell growth                               Putative tumor suppressor                                 Sung et al. ([@B74])
                  RASSF1A        Inhibitor of Ras signaling                             Putative tumor suppressor                                 Jiang et al. ([@B33])
  TRCP4AP/TRUSS   N-Myc, C-Myc   Transcription factors                                  Oncoproteins, multiple tumors                             Choi et al. ([@B12])
  COP1            c-Jun          Transcription factor                                   Oncoprotein, multiple tumors                              Wertz et al. ([@B84])
  COP1            p53            Transcription factor                                   Tumor suppressor                                          Dornan et al. ([@B16])
  COP1            ETV1           Transcription factor                                   Oncoprotein, prostate cancer                              Vitari et al. ([@B81])
  DCAF1/VprBP     unknown        Cell cycle regulator                                   Oncoprotein. Inhibited by the Merlin tumor suppressor     Li et al. ([@B48])
  Cereblon        unknown        Limb development/patterning                            Terotogenic, multiple myeloma. Inhibited by thalidomide   Ito et al. ([@B31])
  Unknown         HOXA9          Transcription factor                                   Acute myeloid leukemia                                    Zhang et al. ([@B89])
  Unknown         p27/Kip1       CDK inhibitor                                          Tumor suppressor                                          Higa et al. ([@B24])
  Unknown         cyclin E       Cell cycle progression                                 Oncoprotein, multiple tumors                              Higa et al. ([@B24])
  Unknown         Chk1           Cell cycle checkpoint kinase                           Tumor suppressor                                          Zhang et al. ([@B90]), Leung-Pineda et al. ([@B44]), Guervilly et al. ([@B20])

The oncogenic effects of CUL4A are highlighted by the finding that Merlin, a tumor suppressor encoded by *NF2*, inhibits the ubiquitin ligase activity of CUL4A in complex with VprBP/DCAF1 (Li et al., [@B48]). Moreover, mutations in Merlin that ablate the enzymatic inhibition of CRL4^VprBP^ have been found in patients with the neurofibromatosis type 2 familial cancer syndrome (Li et al., [@B48]). VprBP silencing compromises tumorigenesis in Merlin-deficient mesothelioma cell lines, indicating the significance of CRL4^VprBP^ signaling in promoting cellular proliferation (Li et al., [@B48]). Huang and Chen showed that Merlin was targeted for degradation by the CRL4^VprBP^ ubiquitin ligase (Huang and Chen, [@B28]). However, Li et al. demonstrated that Merlin was not a substrate of CRL4^VprBP^, but rather served as a negative regulator of the CRL4^VprBP^ ubiquitin ligase. Further biochemical and genetic studies are required to determine the functional relationship between Merlin and CRL4^VprBP^. VprBP is also required for cell cycle progression into S phase (Belzile et al., [@B6]; Hrecka et al., [@B25]; Le Rouzic et al., [@B42]; Tan et al., [@B76]; Wen et al., [@B83]), but the mechanism of cell cycle regulation and the cellular targets of CRL4^VprBP^ have yet to be determined. Nevertheless, these findings indicate a role for the CRL4^VprBP^ ubiquitin ligase in promoting cell cycle progression and oncogenic transformation.

Despite the numerous growth-promoting pathways that are amplified by CUL4A activity, the degradation of other identified CUL4A substrates reveals a more complex effect on growth regulation. CUL4A plays a critical role in granulopoiesis by degrading the HOXA9 homeodomain protein, which may also restrict HOXA9-induced leukemogenesis (Zhang et al., [@B89]). The leukemogenic NUP98--HOXA9 fusion protein, which is derived from the *t*(9;11)(p15;p15) chromosomal translocation in acute myeloid leukemia patients, is resistant to CUL4A-mediated degradation, further indicating that CUL4A may play a role in the proper differentiation of hematopoietic cells (Chung et al., [@B13]). In addition to restricting the NER threshold, CRL4 also responds to DNA damage through histone H3 and H4 ubiquitination, which facilitates the recruitment of repair proteins (e.g., XPC) to damaged DNA (Wang et al., [@B82]). Thus, the CUL4A ubiquitin ligase may play distinct roles in tumorigenesis that are dictated by cellular context or environmental conditions.

CUL4B and Human X-Linked Mental Retardation
===========================================

*CUL4B* mutations in human patients have been found to be causal for X-linked mental retardation (XLMR) syndrome (Tarpey et al., [@B79]; Zou et al., [@B92]; Badura-Stronka et al., [@B5]; Isidor et al., [@B30]). Patient-derived cells also display increased camptothecin-induced topoisomerase I-dependent DNA breaks, which are associated with the peripheral neuropathy spinocerebellar ataxia with axonal neuropathy-1 (SCAN-1; Kerzendorfer et al., [@B38]). The unique CUL4B N-terminus may mediate the recruitment of distinct substrates for degradation, and their accumulation likely contributes to the CUL4B phenotype. WDR5, a subunit of the H3K4 methyltransferase complex, was initially identified as a DCAF and more recently characterized as a CUL4B substrate (Nakagawa and Xiong, [@B55]). XLMR-derived *CUL4B* mutations resulted in the accumulation of WDR5 and subsequent activation of neuronal genes that promote neurite extension. Peroxiredoxin III is another unique CUL4B substrate that may affect neural development through the regulation of reactive oxygen species (ROS) levels (Li et al., [@B47]). Finally, the arylhydrocarbon receptor (AhR) acts as a unique CUL4B substrate receptor that targets estrogen and androgen receptors for proteasome-mediated degradation (Ohtake et al., [@B60]), further highlighting the role of CUL4B as a transcriptional regulator.

Distinct expression patterns may also account for the phenotypes observed in the *Cul4a* knockout mouse model. In addition to enhanced resistance against UV-induced skin carcinogenesis, CUL4A knockout also resulted in male infertility (Kopanja et al., [@B40]; Yin et al., [@B87]). These studies revealed non-overlapping expression patterns between CUL4A and CUL4B during the pachytene to diplotene stages in adult testes, thus accounting for the physiological requirement for CUL4A activity in spermatogenesis (Yin et al., [@B87]). The disease syndrome manifested in humans with CUL4B mutations may be attributed to exclusive substrate targeting and/or differential expression patterns of the CUL4 family members. *In vivo* interrogation of CUL4B activity using knockout mouse models would shed insight into the mechanism of pathology, and may identify avenues for therapeutic intervention.

CRL4 as a Candidate for Therapeutic Intervention
================================================

Manipulation of the post-translational stability of cellular proteins has been demonstrated to be a new and effective cancer therapeutic strategy. Proteasome inhibitors, such as bortezomib, non-specifically block the overall degradation of poly-ubiquitinated proteins, but preferentially sensitize rapidly dividing cells to apoptosis (Richardson et al., [@B65]; Kane et al., [@B36]; Orlowski and Kuhn, [@B61]). MLN4924, a small molecule inhibitor of the Nedd8 E1 activating enzyme, specifically blocks cullin activity, which leads to the accumulation of their substrates (Soucy et al., [@B72]). However, more precise targeting of CRL complexes has been shown to be possible with the discovery that the teratogenic agent thalidomide specifically inhibits Cereblon (CRBN) (Ito et al., [@B31]), an identified DCAF for the CRL4 ubiquitin ligase family. Substrates for CRL4^CRBN^ have yet to be determined, but aberrant Fgf8 expression and signaling were observed following Cereblon inhibition (Ito et al., [@B31]). Thalidomide is currently used to treat multiple myeloma, indicating that Cereblon activity likely promotes cell growth.

Viral hijack of CRL4 activity may provide further insight into possible mechanisms of CRL4 intervention. Parainfluenza virus 5 (PIV5, formerly SV5) V protein binds DDB1, which recruits STAT2 to target STAT1 for ubiquitination and proteasome-mediated degradation, thus inhibiting the cellular interferon-induced response to viral infection (Precious et al., [@B63], [@B64]). Additional rubulaviruses, such as human parainfluenza virus 2 and mumps virus, also target STAT proteins for degradation by redirecting DDB1 activity through their V proteins (Ulane and Horvath, [@B80]). DDB1 binding by the hepatitis B virus X protein (HBx) resulted in S phase arrest (Martin-Lluesma et al., [@B50]), and the subsequent deleterious effects contributed to hepatocellular carcinomas in a cell-non-autonomous manner that was recapitulated in hepatocyte-specific *Ddb1* knockout mice (Yamaji et al., [@B85]). S phase arrest is also triggered by HIV-1 Vpr and HIV-2 Vpx proteins through CRL4^VprBP^ binding, which may promote macrophage infection (Sharifi et al., [@B68]). Thus, the modification of DDB1 substrate binding represents another method of altering CRL4 activity for therapeutic purposes.

Concluding Remarks
==================

Despite the significant sequence conservation and functional redundancy of the CUL4 family members, CUL4A and CUL4B play strikingly diverse roles in human disease. CUL4A activity promotes oncogenesis, as demonstrated by the overexpression and/or amplification of CUL4A in several tumor types and the resistance to UV-induced skin carcinogenesis in the *Cul4a* knockout mouse model, while loss-of-function mutations in CUL4B are causal for human X-linked mental retardation syndrome. Surprisingly, gene-trapped inactivation of *Cul4b* in mice resulted in embryonic lethality (Cox et al., [@B14]). The genetic interrogation of CUL4B awaits the generation of a conditional *Cul4b* knockout mouse model to identify the unique *in vivo* contributions of CUL4B activity, and the major substrates that are responsible for CUL4B-dependent disease phenotypes. Furthermore, additional mouse models are required to gain a comprehensive understanding of the role of CRL4 in pathogenesis through the functional delineation of the DCAF substrate receptors, their substrates (Emanuele et al., [@B17]), and the associated cellular pathways whose dysregulation contribute to pathogenesis.

CUL4A represents an ideal target for therapeutic intervention, as genetic ablation in mice resulted in a marked resistance to carcinogenesis. Additionally, the recent structural determination of CRL4 assembly and activation provides a molecular platform for the design of inhibitors (Angers et al., [@B4]; Li et al., [@B45]; Fischer et al., [@B18]). Although the extensive protein--protein interface between CUL4 and DDB1 may present a formidable challenge for direct intervention by small molecule inhibitors, allosteric inhibitors are an attractive alternative to attenuate CRL4 activity, especially given the stringent requirements of proximity and E2--E3 orientation for effective ubiquitin transfer. Finally, the striking efficacy of thalidomide in treating multiple myeloma and its inhibition of Cereblon activity indicate that developing specific inhibitors for multiple subunits or interfaces, e.g., DCAF binding to either CRL4 or substrates, may prove to be feasible therapeutic strategies.
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